Finbar  Larkin net worth and biography

Finbar Larkin Biography and Net Worth

Finbar Larkin, Ph.D., was appointed Senior Vice President, Technical Operations in October 2019. He has been a member of the Jazz family since 2013 and has made significant contributions to Jazz’s evolution and transformation to an innovative Biopharma company. He built the pharmaceutical development and manufacturing science organization responsible for Chemistry Manufacturing and Controls (CMC) activities related to development, approval and launch of Sunosi, Xywav, Defitelio and Vyxeos. Dr. Larkin has responsibility for global pharmaceutical CMC development, manufacturing, supply chain, and new product and technology integration.

Dr. Larkin was appointed our Senior Vice President, Technical Operations in October 2019. Dr. Larkin previously served as our Senior Vice President, Pharmaceutical Development & Manufacturing Science from September 2018 until October 2019, our Vice President, Technical Development from February 2014 until August 2018, and our Executive Director, Technical Operations from April 2013 until February 2014. Prior to that, from September 2009 until March 2013, Dr. Larkin served in management roles at Ipsen Pharma SAS, culminating in his role as Vice President, Engineering & Senior Specialist. From February 1997 until August 2009, he served as Vice President and Managing Director at Ipsen Manufacturing Ireland. From 1990 until 1997, he served in various project and operational management roles at Novartis. Prior to 1990, Dr. Larkin served in various roles in manufacturing science and technology, human resources and quality & analytical science at Lilly SA. Dr. Larkin received a B.Sc. and Ph.D. in Chemistry from University College Dublin.

What is Finbar Larkin's net worth?

The estimated net worth of Finbar Larkin is at least $2.87 million as of March 6th, 2023. Dr. Larkin owns 23,854 shares of Jazz Pharmaceuticals stock worth more than $2,872,499 as of March 29th. This net worth approximation does not reflect any other investments that Dr. Larkin may own. Learn More about Finbar Larkin's net worth.

How do I contact Finbar Larkin?

The corporate mailing address for Dr. Larkin and other Jazz Pharmaceuticals executives is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. Jazz Pharmaceuticals can also be reached via phone at (531) 634-7800 and via email at [email protected]. Learn More on Finbar Larkin's contact information.

Has Finbar Larkin been buying or selling shares of Jazz Pharmaceuticals?

Finbar Larkin has not been actively trading shares of Jazz Pharmaceuticals during the last ninety days. Most recently, Finbar Larkin sold 1,706 shares of the business's stock in a transaction on Monday, March 6th. The shares were sold at an average price of $143.92, for a transaction totalling $245,527.52. Following the completion of the sale, the senior vice president now directly owns 23,854 shares of the company's stock, valued at $3,433,067.68. Learn More on Finbar Larkin's trading history.

Who are Jazz Pharmaceuticals' active insiders?

Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Robert Iannone (EVP), Finbar Larkin (SVP), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Jazz Pharmaceuticals?

During the last year, Jazz Pharmaceuticals insiders bought shares 1 times. They purchased a total of 12,000 shares worth more than $1,435,800.00. During the last year, insiders at the specialty pharmaceutical company sold shares 10 times. They sold a total of 13,870 shares worth more than $1,827,470.63. The most recent insider tranaction occured on March, 6th when CAO Patricia Carr sold 1,936 shares worth more than $231,623.04. Insiders at Jazz Pharmaceuticals own 4.4% of the company. Learn More about insider trades at Jazz Pharmaceuticals.

Information on this page was last updated on 3/6/2024.

Finbar Larkin Insider Trading History at Jazz Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/6/2023Sell1,706$143.92$245,527.5223,854View SEC Filing Icon  
11/14/2022Sell197$149.33$29,418.0119,409View SEC Filing Icon  
9/7/2022Sell63$150.00$9,450.0019,606View SEC Filing Icon  
5/9/2022Sell1,747$148.94$260,198.1819,462View SEC Filing Icon  
11/12/2021Sell197$135.79$26,750.63View SEC Filing Icon  
9/8/2021Sell63$134.51$8,474.13View SEC Filing Icon  
11/6/2020Sell197$151.93$29,930.2113,964View SEC Filing Icon  
9/9/2020Sell63$138.53$8,727.39View SEC Filing Icon  
3/9/2020Sell615$111.49$68,566.3514,498View SEC Filing Icon  
3/6/2020Sell292$119.15$34,791.8014,498View SEC Filing Icon  
3/3/2020Sell279$119.75$33,410.2514,790View SEC Filing Icon  
See Full Table

Finbar Larkin Buying and Selling Activity at Jazz Pharmaceuticals

This chart shows Finbar Larkin's buying and selling at Jazz Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Jazz Pharmaceuticals Company Overview

Jazz Pharmaceuticals logo
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $120.42
Low: $120.03
High: $121.53

50 Day Range

MA: $122.70
Low: $115.79
High: $132.77

2 Week Range

Now: $120.42
Low: $111.25
High: $147.98

Volume

403,590 shs

Average Volume

629,391 shs

Market Capitalization

$7.59 billion

P/E Ratio

19.68

Dividend Yield

N/A

Beta

0.59